A Study of Guselkumab in Participants With Active Psoriatic Arthritis

3期进行中（已停止招募） NCT04882098

适应症	Arthritis, Psoriatic
分期	3期
申办方	Janssen Research & Development, LLC
状态	进行中（已停止招募）
受试者人数	1,054 人
干预（药物）	Guselkumab
开始日期	2021年6月17日
完成日期	2024年12月30日
结果公布日	2026年2月4日

摘要

The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.

Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24

At Week 24 · percentage of participants

Group 1: Guselkumab 100 mg q8w	68.3 percentage of participants
Group 2: Guselkumab 100 mg q4w	66.6 percentage of participants
Group 3: Placebo Followed by Guselkumab	47.0 percentage of participants

p-value	<0.001
Difference in percentage	21.3 (95% CI 14.4–28.2)

在 BENITIONS 中查看查看 ClinicalTrials.gov 原文

同一适应症的其他试验

A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab i — UCB Biopharma SRL
A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoria — Janssen Pharmaceutical K.K.
A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoria — Janssen Research & Development, LLC
A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects Wi — UCB Biopharma SRL
A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With A — UCB Biopharma SRL
The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis — Hangzhou Highlightll Pharmaceutical Co., Ltd

全部试验

本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。

English 한국어 日本語中文 Русский